Navigation Links
Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands

CLEVELAND, June 6, 2011 /PRNewswire/ -- Ganeden Biotech announced the sale of its leading Sustenex® and Digestive Advantage® brands of probiotic dietary supplements to Schiff Nutrition International, Inc. for $40 million in cash.  Ganeden will also receive royalties on Schiff products containing GanedenBC30™.  The sale includes the worldwide exclusive rights to use Ganeden's probiotic technology, GanedenBC30™, in the over-the-counter (OTC) and dietary supplement space.  Ganeden and Schiff also intend to collaborate on extending the use of OTC probiotic technologies into new areas of human health.


The capital from the sale and royalties will accelerate the commercialization of Ganeden's remaining high-growth portfolio, including its rapidly expanding food and beverage probiotic ingredients business, its recently launched enLiven™ probiotic yogurt brand, its Ganpro™ line of Direct Fed Microbial feed additives, its clinical-stage entries into the cardiovascular health market, and various feminine health, topical, and cosmetic applications.

Over the past three years, Sustenex® and Digestive Advantage® combined to make Ganeden the largest seller of OTC probiotics in the retail mass market on a unit basis. Consumer loyalty for Ganeden's OTC probiotics, as measured by repeat purchase rate, grew to be the second highest among the top 50 brands of OTC gastrointestinal products sold in the United States.

"After achieving a leading market position with our Sustenex® and Digestive Advantage® brands with a very limited marketing spend, we believed it was the right time to sell these brands to a partner that will provide incremental marketing support, which will substantially increase the number of consumers who will benefit from the daily use of our probiotics," said Andrew Lefkowitz, Ganeden's President and CEO.

"Although Ganeden has already been awarded over 100 patents around the world and published 13 studies in peer-reviewed journals, this transaction will also give us the capital needed to further substantiate the efficacy of GanedenBC30™ in a broad range of human and animal health applications through greater focus on our scientific expertise," Lefkowitz added.

About Ganeden Biotech

Ganeden Biotech is a Cleveland, Ohio, based company that markets enLiven™ probiotic yogurt in Walmart stores nationally and licenses its patented strain of probiotic bacteria, GanedenBC30™, for use in branded food and beverage applications. Ganeden also markets its Ganpro™ brand of direct fed microbial as an alternative to traditional antibiotic use. Ganeden licenses its technology directly and through select distributors such as Glanbia Nutrition, PL Thomas, Sochim, and Pathway International.  GanedenBC30™ is also known as Bacillus coagulans GBI-30, PTA-6086.  Clinical trials show that GanedenBC30™ is effective in irritable bowel syndrome (IBS), intestinal gas, and in boosting the immune system against cold and flu viruses.  GanedenBC30™ is currently being studied in IBS and depression by researchers at the Massachusetts General Hospital and in HIV infection by researchers at the AIDS Healthcare foundation.  For more information, visit

SOURCE Ganeden Biotech
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
2. Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener
3. Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology
4. Ganeden Biotech Introduces GanPro(TM) Direct-Fed Microbial for Livestock
5. Ganeden Biotech Introduces the First Probiotic Thin Strip
6. Ganeden Biotech Granted 100th Probiotic Patent
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Yongye Biotechnology International Retains CCG Investor Relations
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):